What question did this study set out to answer?

Evaluate the therapeutic efficacy of targeted KRASG12V oncoprotein degradation and investigate the mechanisms of acquired resistance in lung adenocarcinoma.

August 16, 2026Cancer Research

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma

View Full Paper

Ask AI

Bookmark

Evaluate the therapeutic efficacy of targeted KRASG12V oncoprotein degradation and investigate the mechanisms of acquired resistance in lung adenocarcinoma.
Generated and utilized a dTAG-KRASG12V syngeneic mouse model to evaluate targeted KRASG12V protein degradation in vivo.
Assessed tumor regression, cellular intrinsic responses, microenvironment remodeling, and acquired resistance pathways under prolonged PROTAC treatment.
Degrading the KRASG12V oncoprotein caused significant lung adenocarcinoma tumor regression driven primarily by cancer cell-intrinsic mechanisms alongside tumor microenvironment remodeling.
Prolonged PROTAC exposure led to acquired resistance and disease relapse driven by dysregulation of the ubiquitin-proteasome system.
Resistant tumors maintained dependency on the KRAS oncoprotein and remained sensitive to conventional KRAS small-molecule inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates that targeted KRASG12V degradation drives tumor regression in lung adenocarcinoma models, indicating distinct resistance mechanisms from standard inhibitors.

Cite This Study

Borrego et al. (2026) studied this question.

synapsesocial.com/papers/6a817a60f2fb91fc834ae164 https://doi.org/10.1158/0008-5472.can-26-2186

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that targeted KRASG12V degradation drives tumor regression in lung adenocarcinoma models, indicating distinct resistance mechanisms from standard inhibitors.

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma

Key Points

Discussion

Implication

Cite This Study

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider